Form 4: Elevance Health Director Acquires Phantom Stock

Elevance Health Director Steven H. Collis was granted 639 phantom stock units as part of the company's Board of Directors Compensation Program, effective August 1, 2025.

Summary

• Steven H. Collis, a Director of Elevance Health, Inc. (ELV), is scheduled to acquire 639 phantom stock units on August 1, 2025.
• These units are granted at a price of $0, indicating they are part of a compensation program rather than a purchase.
• The phantom stock units are accrued under the Elevance Health, Inc. Board of Directors Compensation Program.
• They will be payable in Company common stock upon the earlier of five years from the director's election date or when the reporting person ceases to be a board member, unless a later date is designated in the Reporting Person's election under the Company's Board of Directors Deferred Compensation Plan.
• Following this transaction, Steven H. Collis will beneficially own 639 direct phantom stock units.

Sentiment

Score: 7

Explanation: This filing reflects a standard, positive corporate governance practice where director compensation includes equity-based awards, aligning the director's long-term interests with shareholder value. It is a routine transaction and does not indicate any negative operational or financial issues.

Positives

• The grant of phantom stock units aligns the director's interests with long-term shareholder value, as the units are payable in common stock upon vesting conditions.
• This is a standard component of director compensation, indicating a structured approach to rewarding board service and retaining key personnel.

Negatives

• No direct negative implications are apparent from this routine compensation filing.

Risks

• This Form 4 filing does not disclose specific risks beyond the inherent risks associated with equity compensation, such as stock price fluctuations impacting the value of the units upon vesting.

Future Outlook

The phantom stock units are scheduled to become payable in Elevance Health common stock upon the earlier of five years from the director's annual meeting election date or the date the reporting person ceases to be a member of the company's board of directors, unless a later date is designated in the Reporting Person's election under the Company's Board of Directors Deferred Compensation Plan. This indicates a future vesting and payout schedule for the compensation.

Management Comments

• No specific management comments or quotes are provided in this Form 4 filing, which is a transactional report.

Industry Context

The grant of phantom stock units to a director is a common practice in the healthcare industry and broader corporate landscape, aligning executive and board incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• The grant of phantom stock units as part of director compensation is a standard practice across large publicly traded companies, including those in the healthcare sector like UnitedHealth Group (UNH) or Cigna Group (CI), which often use similar equity-based incentives to retain and motivate board members.
• The $0 acquisition price is typical for compensation grants, reflecting a non-cash award tied to future performance or service.

Corporate Governance

Related Party Transactions

• Acquisition of 639 phantom stock units by Director Steven H. Collis from Elevance Health, Inc. as part of the Board of Directors Compensation Program.

Stakeholder Impact

• Shareholders: The equity-based compensation aligns the director's interests with long-term shareholder value, potentially fostering better governance and strategic decisions.
• Director: Receives compensation in the form of phantom stock units, incentivizing continued service and performance.

Next Steps

• Phantom stock units will become payable in common stock upon the earlier of five years from the director's election date or cessation of board membership, unless a later date is designated by the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine grant of phantom stock units to a director as part of their compensation. It does not contain any new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. It primarily serves to disclose insider transactions, which in this case, is a standard equity award designed to align director interests with long-term shareholder value. Therefore, a "hold" recommendation is appropriate as there's no new catalyst for a buy or sell decision.

Keywords

Elevance Health, ELV, Director Compensation, Phantom Stock, SEC Form 4, Insider Transaction, Corporate Governance, Equity Compensation